Is Late Prevention of Cerebral Palsy in Extremely Preterm Infants Plausible?


Journal

Developmental neuroscience
ISSN: 1421-9859
Titre abrégé: Dev Neurosci
Pays: Switzerland
ID NLM: 7809375

Informations de publication

Date de publication:
2022
Historique:
received: 02 10 2021
accepted: 16 12 2021
pubmed: 23 12 2021
medline: 15 9 2022
entrez: 22 12 2021
Statut: ppublish

Résumé

Preterm birth continues to be associated with neurodevelopmental problems including cerebral palsy. Cystic white matter injury (WMI) is still the major neuropathology underlying cerebral palsy, affecting 1-3% of preterm infants. Although rates have gradually fallen over time, the pathogenesis and evolution of cystic WMI are still poorly understood. Hypoxia-ischemia (HI) remains an important contributor, yet there is no established treatment to prevent injury. Clinically, serial ultrasound and magnetic resonance imaging studies typically show delayed development of cystic lesions 2-4 weeks after birth. This raises the important and unresolved question as to whether this represents slow evolution of injury occurring around the time of birth or repeated injury over many weeks after birth. There is increasing evidence that tertiary injury after HI can contribute to impairment of white and grey matter maturation. In the present review, we discuss preclinical evidence that severe, cystic WMI can evolve for many weeks after acute HI and is associated with microglia activity. This suggests the intriguing hypothesis that the tertiary phase of injury is not as subtle as often thought and that there may be a window of therapeutic opportunity for 1 to 2 weeks after hypoxic-ischemic injury to prevent delayed cystic lesions, and so, further reduce the risk of cerebral palsy after preterm birth.

Identifiants

pubmed: 34937030
pii: 000521618
doi: 10.1159/000521618
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-185

Informations de copyright

© 2021 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Benjamin A Lear (BA)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Christopher A Lear (CA)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Simerdeep K Dhillon (SK)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Joanne O Davidson (JO)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Laura Bennet (L)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Alistair J Gunn (AJ)

The Department of Physiology, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH